Michelle Petri, MD MPH
Professor Michelle Petri, MD, MPH
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Michelle Petri is a Professor of Medicine in the Division of Rheumatology and Director of the Lupus Center at the Johns Hopkins University School of Medicine and Johns Hopkins Hospital in Baltimore, Maryland. She earned her medical degree from Harvard Medical School in Boston, Massachusetts, and completed her internship and residency in Internal medicine at Massachusetts General Hospital. Thereafter, Professor Petri completed her Postdoctoral Fellowship in Allergy, Immunology, and Rheumatology at the University of California, San Francisco. She subsequently earned her master’s in Public Health and Epidemiology from Johns Hopkins University Bloomberg School of Public Health. Professor Petri’s research focuses on several aspects of systemic lupus erythematosus (SLE), including atherosclerosis, antiphospholipid syndrome (APS), lupus nephritis, and pregnancy. The Hopkins Lupus Cohort, started by Professor Petri in 1987, is a longitudinal study of the incidence and pathogenesis of thrombotic events and coronary artery disease in SLE. She is a Master of the American College of Rheumatology, and was Chair of the Lupus Now Education Program.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:SLEDate added:01/21/2024Date updated:01/21/2024Relationship end date:10/31/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AuriniaTopic:SLEDate added:01/21/2024Date updated:01/21/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Eli LillyTopic:SLEDate added:01/21/2024Date updated:01/21/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ExagenTopic:SLEDate added:01/21/2024Date updated:01/21/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GSKTopic:SLEDate added:01/21/2024Date updated:01/21/2024Relationship end date:10/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:JanssenTopic:SLEDate added:01/21/2024Date updated:01/21/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AmgenTopic:SLEDate added:01/21/2024Date updated:01/21/2024Relationship end date:04/30/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AnaptysBioTopic:SLEDate added:01/21/2024Date updated:01/21/2024Relationship end date:01/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Annexon BioTopic:SLEDate added:01/21/2024Date updated:01/21/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:ArgenxTopic:SLEDate added:01/21/2024Date updated:01/21/2024